CompletedPhase 2NCT02893930

Sapanisertib in Treating Patients With Metastatic or Refractory Pancreatic Neuroendocrine Tumor That Cannot Be Removed by Surgery

Studying Neuroendocrine carcinoma of pancreas

Last synced from ClinicalTrials.gov

Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing data

Key facts

Sponsor
National Cancer Institute (NCI)
Principal Investigator
Lakshmi Rajdev
ECOG-ACRIN Cancer Research Group
Intervention
Sapanisertib(drug)
Enrollment
13 enrolled
Eligibility
18 years · All sexes
Timeline
20172022

Study locations (30)

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT02893930 on ClinicalTrials.gov

Other trials for Neuroendocrine carcinoma of pancreas

Additional recruiting or active studies for the same condition.

See all trials for Neuroendocrine carcinoma of pancreas

← Back to all trials